Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr;46(4):447-448.
doi: 10.1007/s00270-023-03409-x. Epub 2023 Mar 17.

Drug-Eluting Microspheres and Hepatocellular Carcinoma: Improving Outcomes Related to Drug or Better Practice?

Zeyad A Metwalli  1 , Ryan M Davis  2 , Sanjit O Tewari  3
Affiliations
Editorial

Drug-Eluting Microspheres and Hepatocellular Carcinoma: Improving Outcomes Related to Drug or Better Practice?

Zeyad A Metwalli et al. Cardiovasc Intervent Radiol. 2023 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Veloso Gomes F, de Baère T, Verset G, et al. Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: a pooled multicentric analysis of survival in 580 patients. Cardiovasc Intervent Radiol. 2023. https://doi.org/10.1007/s00270-023-03362-9 . - DOI - PubMed
    1. Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D’Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O’Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–53. https://doi.org/10.1200/JCO.2015.64.0821 . (Epub 2016 Feb 1. PMID: 26834067; PMCID: PMC4966514). - DOI - PubMed - PMC
    1. Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699–710. https://doi.org/10.1148/radiol.211806 . (Epub 2022 Mar 8 PMID: 35258371). - DOI - PubMed
    1. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-1163.e2. https://doi.org/10.1053/j.gastro.2016.08.029 . (Epub 2016 Aug 27. PMID: 27575820; PMCID: PMC5124387). - DOI - PubMed
    1. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342–52. https://doi.org/10.1002/hep.31819 . (Epub 2021 Jun 11. PMID: 33739462; PMCID: PMC8596669). - DOI - PubMed

LinkOut - more resources